{"brief_title": "Prevention Of Recurrence Of Atrial Fibrillation", "brief_summary": "The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).", "condition": "Fibrillation, Atrial", "intervention_type": "Other", "intervention_name": "Placebo", "description": "Placebo to match SB-207266", "arm_group_label": "Arm 2", "criteria": "Inclusion Criteria: - Symptomatic persistent atrial fibrillation requiring DC cardioversion. - Duration of AF >48 hrs. <6 months Exclusion Criteria: - Concomitant Class I and/or III anti-arrhythmic drugs. - Amiodarone treatment within 3 months of the study. - Other inclusion or exclusion criteria to be determined by the physician and study sponsor.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00041496.xml"}